Présentation

W1.3 A novel vaccine technology platform Plasmid Launched Live Attenuated Virus (PLLAV) Vaccines

Johan Neyts, Kai Dallmeier

Workshop presentation

Auteurs

Langues

  • Anglais

Année de publication

2018

Type

Présentation

Catégories

  • Initiatives mondiales

GVIRF-2018

Cette ressource apparaît sur le Thème suivant:

Cette ressource est incluse dans le tableau suivant:

TitreAuteurAnnéeTypeLangue
W9.4 Antibody Engineering: Optimization of Antibodies for CommercializationStephen Hadley2018PresentationAnglais
W9.3 Monoclonal Antibodies for Influenza Prevention, Therapy, or Vaccine Antigen DesignBruce Innis2018PresentationAnglais
W9.2 Monoclonal antibodies for rabies post-exposure prophylaxisErin Sparrow2018PresentationAnglais
W9.1 Pipeline of HIV monoclonal antibodies for prevention of HIVBarney Graham2018PresentationAnglais
W8.3 The Principle and Process of Autogenous VaccineSuphot Wattanaphansak2018PresentationAnglais
W8.2 Vaccination against bacterial diseases in farmed Atlantic salmon: experience and global applicabilityEdgar Brun2018PresentationAnglais
W8.1 Antimicrobial Resistance and VaccinesDennis Dixon2018PresentationAnglais
W7.5 Target Value PropositionJean Lang2018PresentationAnglais
W7.4 Human Hookworm Vaccine Initiative: a Public Health value proposition leading to societal impact and positive financial returnsMaria Elena Bottazzi2018PresentationAnglais
W7.3 A Hepatitis C Virus Vaccine UpdateAndrea Cox2018PresentationAnglais
W7.2 Update on RSV Vaccine and mAb developmentRuth Karron2018PresentationAnglais
W7.1 Global Vaccine Pipeline and Value PropositionDavid Kaslow2018PresentationAnglais
W6.3 Maternal and adolescents immunization - a global challengeRaymond Hutubessy2018PresentationAnglais
W6.2 Adolescent Immunization in Developing Countries: Obstacles and OpportunitiesHartono Gunardi2018PresentationAnglais
W6.1 Reaching Adolescents & Pregnant Women (Introduction)Odile Leroy2018PresentationAnglais
W5.4 Universal Influenza Vaccines and Their Role in PreparednessJennifer Gordon2018PresentationAnglais
W5.3 Epidemic Preparedness: National Security for ThailandPunee Pitisuttithum2020PresentationAnglais
W5.2 Influenza Pandemic Risk and PreparednessJohn S. Tam2018PresentationAnglais
W5.1 WHO R&D Blueprint Update: progress and PlansMartin Friede2018PresentationAnglais
W4.4 RTS,S Malaria Vaccine: Toward an understanding of the immunologic basis of protectionChristian Ockenhouse2018PresentationAnglais
W4.3 New technologies for studying human immunityLisa Wagar2018PresentationAnglais
W4.1 New Approaches to Understanding Human ImmunityAnnie Mo2018PresentationAnglais
W3.3 The Future of Pneumococcal Conjugate VaccinesKeith Klugman2018PresentationAnglais
W3.2 Rollout of Pneumococcal Conjugate Vaccine in IndiaNarendra K Arora, Pradeep Haldar2018PresentationAnglais
W3.1 2018 Status of Pneumococcal Conjugate Vaccine Use and ImpactKatherine L. O'Brien2018PresentationAnglais
W2.3 Controlled Human Infection Models and Enteric Vaccine DevelopmentBeth Kirkpatrick2018PresentationAnglais
W2.2 Subunit vaccine technologies for bacterial enteric diseases: Shigella, ETEC and nontyphoidal Salmonella vaccinesCal MacLennan2018PresentationAnglais
W2.1 An update on rotavirus vaccinesGagandeep Kang2018PresentationAnglais
W1.3 A novel vaccine technology platform Plasmid Launched Live Attenuated Virus (PLLAV) VaccinesJohan Neyts, Kai Dallmeier2018PresentationAnglais
W1.2 New Vaccine Strategies using cytomegalovirusKlaus Früh2018PresentationAnglais
W1.1 MIMIC: an in vitro model of human immunityDon Drake2018PresentationAnglais
W9 Antibody-Mediated PreventionNina Russell2018ReportAnglais
W8 Vaccines and Antimicrobial Resistance (AMR)A. A. Adeyemo2018ReportAnglais
W7 New Vaccine Pipeline: Lessons Learned and Accelerating ProgressJean-Pierre Amorij2018ReportAnglais
W6 Reaching Adolescents and Pregnant WomenOdile Leroy2018ReportAnglais
W5 Epidemic and Pandemic PreparednessMartin Friede2018ReportAnglais
W4 Immunological Principles of Vaccines and VaccinationAnnie Mo, Bernhards Ogutu2018ReportAnglais
W3 Pneumococcal Vaccines: Lessons Learned and the Road AheadHani Kim2018ReportAnglais
W1 Emerging Vaccine Strategies & TechnologiesPaula Bryant2018ReportAnglais
P7 Discussion with Thought LeadersPeter Dull2018ReportAnglais
P6.5 Research for polio policy making: Lessons learnedRoland Sutter2018PresentationAnglais
P6.4 Polio Vaccines - R&D UpdatesPeter Dull2018PresentationAnglais
P6.3 Two years after the tOPV ot bOPV switch: What happened to Poliovirus Type 2?Ondrej Mach2018PresentationAnglais
P6.2 Global tOPV withdrawal: "The Switch" experienceAlejandro Ramirez Gonzalez2018PresentationAnglais
P6.1 Intro Polio Endgame: Needs and OpportunitiesRoland Sutter2018PresentationAnglais
P6 Polio Endgame: Needs and OpportunitiesRoland SutterReportAnglais
P5.2 Evidence for Decision MakingYot Teerawattananon2018PresentationAnglais
P5.1 Development of WHO Full Public Health Value Propositions for vaccines to prevent infectious diseasesDavid Kaslow2018PresentationAnglais
P5 Evidence for Decision MakingDavid Kaslow, Robert BreimanReportAnglais
P4.3 Human Clinical Trial to Support the Development of New Vaccines: Perspective from ThailandAkanid Wapeewuttikorn2018PresentationAnglais

Ajouté par: Angela Hwang

Ajouté le: 2022-03-02 06:27:55

Consultations: 1768

Fichier téléchargé

W1-3Neyts.pdf

Cliquez pour télécharger

Ajouter une ressource